Drug Trial Radar · NCT05296733
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
Last checked: Nov 19, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Apr 27, 2022
Primary completion
Dec 29, 2023
Study completion Dec 29, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts. The purpose of Part 1 is to find out whether having liver problems influences how BI 456906 is taken up in the body. The purpose of Part 2 is to find out whether having liver problems influences how people with overweight and obesity tolerate different doses of BI 456906. In Part 1, participants get a single injection of BI 456906 under their skin and stay at the study site for 2 nights afterwards. They are in the study for about a month. During this time, they visit the study site about 8 more times. The doctors compare the amount of BI 456906 in the blood of healthy people and people with liver problems. In Part 2, participants get 1 or 2 injections of BI 456906 once a week under their skin for 28 weeks. At the beginning, they get lower doses of BI 456906. Over time, they get higher doses until they reach a certain dose of BI 456906. This dose is then maintained until the end of the treatment. Participants in Part 2 are in the study for about 7 months. During this time, they visit the study site about 16 times and get about 15 phone calls from the site staff. The doctors record the number of people with health problems that could have been caused by treatment with BI 456906. They compare the results between participants with liver problems and those without liver problems. In both parts, doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Healthy
- Liver Diseases
- Obesity
Interventions
BI 456906Drug
BI 456906
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)Time frame: Up to 360 hours
- Part A: Maximum measured concentration of BI 456906 in plasma (Cmax)Time frame: Up to 360 hours
- Part B: Percentage of patients treated who experience treatment-emergent adverse eventTime frame: Up to Day 218
Locations
13 sites in 6 countries. Site status is shown where the registry gives one.
Arizona Liver Health
Chandler, Arizona
Covenant Metabolic Specialists, LLC
Fort Myers, Florida
Covenant Metabolic Specialists, LLC
Sarasota, Florida
American Research Corporation at the Texas Liver Institute
San Antonio, Texas
IMA Clinical Research San Antonio
San Antonio, Texas
Universitätsklinikum Bonn AöR
Bonn, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitätsklinikum Ulm
Ulm, Germany
Semmelweis University
Budapest, Hungary
CRU Hungary Ltd.
Kistarcsa, Hungary
New Zealand Clinical Research (NZCR)
Auckland, New Zealand
Dr. Piotr Napora, Center of Clinical Research
Wroclaw, Poland
SUMMIT CLINICAL RESEARCH, s.r.o.
Bratislava, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.